The Leeper laboratory studies the vascular biology of atherosclerosis and aneurysm disease.  We are interested in the molecular mechanisms that mediate vascular disease, and developing new translational therapies directed against them.  Our group uses a combination of hypothesis-free genetic approaches, favoring the concept that insights generated in this manner are likely to have relevance to human disease.  Currently, our major focus is on the chromosome 9p21 locus, which is widely recognized as the most important heritable cardiovascular locus identified through genome-wide association studies (GWAS).   We seek to fully explain how this locus - which affects over 20% of the population - potentiates coronary disease, stroke and aneurysms, and does so independently of all classical risk factors.   Our group pursues the goal of true ‘bench-to-bedside’ translation, and includes a basic genetics, molecular biology and mouse model team, as well as a translational Vascular Medicine team which performs early-phase clinical research.  Ultimately, we seek to develop a platform of new therapies directed against atherosclerosis, which is now the leading killer worldwide. 


News, Events, & Team Milestones

Publication in Nature

Experimental anticancer drug may tackle heart disease, too.  

2017 American Heart Association (AHA) Scientific Sessions

Congratulations to Leeper lab members Vivek Nanda and Alyssa Flores for being selected for travel awards funding their travel to attend the 2017 American Heart Association (AHA) Scientific Sessions November 11-15, 2017 in Anaheim, CA.

Dr. Nick Leeper, appointed to the Society of Vascular Medicine Board of Trustees

Dr. Nick Leeper was appointed to the Society for Vascular Surgery Medicine Board of Trustees.  We offer Dr. Leeper a huge congratulations on this distinguished appointment.   

Dr. Eri Fukaya, appointed to the AHA PVD Early Career Committee

Congratulations to Dr. Eri Fukaya on her appointment to the American Heart Association (AHA), Council on Peripheral Vascular Disease (PVD), Early Career Committee.